Education
About Us
Working with TipRanks
Follow Us
Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
RVPH Stock Chart & Stats
$0.80
-$0.09(-4.50%)
At close: 4:00 PM EST
$0.80
-$0.09(-4.50%)
Day’s Range― - ―
52-Week Range$0.67 - $23.40
Previous CloseN/A
Volume1.63M
Average Volume (3M)14.40M
Market Cap
$4.60M
Enterprise Value-$10.46M
Total Cash (Recent Filing)$13.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 23, 2026EPS Estimate
-1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,752,931
10 Day Avg. Volume22,198,486
30 Day Avg. Volume14,401,288
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)73.84
Price to Sales (P/S)0.00
P/FCF Ratio-1.79
Enterprise Value/Market Cap-2.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$2.13Price Target Upside166.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-driven Patient SelectionIdentification of speech latency as a predictive biomarker enables selection of patients with more severe negative symptoms, improving trial enrichment and the likelihood of a clearer treatment signal versus placebo.
Peer-reviewed ValidationPublication in an Elsevier outlet increased visibility and validated the vocal biomarker from the Phase 3 study, strengthening scientific credibility for the program.
Regulatory Guidance For Study DesignFDA guidance on data analysis, presentation, and specific study requirements clarified expectations and established a clearer regulatory pathway for registrational work.
Bears Say
Expanded Safety And Efficacy Data NeedsRegulatory requests to generate additional efficacy data and expand the safety dataset may require larger enrollment and longer follow-up, raising trial cost and approval uncertainty.
Financing RiskLimited cash runway makes additional financing likely to be required to fund the next Phase 3 study, creating risk of dilution or delays.
Regulatory Requirement For Additional TrialFDA recommendation for a second confirmatory Phase 3 trial imposes a mandatory registrational study that increases development time and resource needs.
Reviva Pharmaceuticals Holdings News
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.67 and its highest was $23.40 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $4.60M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Mar 23, 2026 which is today.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Currently, no data Available
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Undervalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -1.09.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 5,752,931 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Currently, no hedge funds are holding shares in RVPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
RVPH Stock 12 Month Forecast
Average Price Target
$2.13
▲(166.25% Upside)
Technical Analysis
Cel-Sci
―
Plus Therapeutics
―
XBiotech
―
Prelude Therapeutics
―
Coeptis Therapeutics Holdings
―
Ownership Overview
Currently, No data available
---